| Identification | Back Directory | [Name]
H-TYR-LEU-OH | [CAS]
17355-10-1 | [Synonyms]
YL
TYR-LEU
H-TYR-LEU-OH
tyrosylleucine
tyr-leucrystalline
L-TYROSYL-L-LEUCINE
L-Leucine, L-tyrosyl-
L-Leucine, N-L-tyrosyl-
TYR-LEU 99% CRYSTALLINE
(S)-2-((S)-2-AMino-3-(4-hydroxyphenyl)propanaMido)-4-Methylpentanoic acid | [Molecular Formula]
C15H22N2O4 | [MDL Number]
MFCD00037194 | [MOL File]
17355-10-1.mol | [Molecular Weight]
294.35 |
| Chemical Properties | Back Directory | [Melting point ]
280 °C (sublm)(Solv: water (7732-18-5)) | [Boiling point ]
575.9±50.0 °C(Predicted) | [density ]
1.218±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [form ]
Solid | [pka]
3.12±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(S)-2-((S)-2-Amino-3-(4-hydroxyphenyl)propanamido)-4-methylpentanoic Acid is a pharmaceutical agent with ACE inhibitory properties. | [Definition]
ChEBI: A dipeptide formed from L-tyrosine and L-leucine residues. | [in vivo]
Tyrosylleucine (YL), administered orally, intracerebroventricularly, or intraperitoneally exhibits a potent antidepressant-like activity in the forced swim and tail suspension tests in na ve mice[1]. | Animal Model: | Male ddY mice (24-27?g)[1] | | Dosage: | 0.1-30?mg/kg, i.p.; 0.1-1.0 nmol/mouse, i.c.v.; 30-100?mg/kg, p.o. | | Administration: | Administered orally, intracerebroventricularly, or intraperitoneally | | Result: | Decreased immobility time after intraperitoneal (1-30?mg/kg) and intracerebroventricular (0.3-1 nmol/mouse) administrations in the FST.
Exhibited a potent antidepressant-like activity in the forced swim and tail suspension tests in na?ve mice.
|
|
|
| Company Name: |
Nextpeptide Inc
|
| Telephone: |
+86-0571-81612335 +8613336028439 |
| Website: |
http://www.nextpeptide.com/ |
| Company Name: |
Ontores Biotech
|
| Telephone: |
0571-88760729 18072970094 |
| Website: |
www.ontoresinc.cn |
|